Other

Pieris Pharmaceuticals Gmbh

Michaela Aloe

Andrea Allersdorfer

Marlon Hinner

Alexander Wiedenmann

Gabriele Matschiner

Rachida Siham Bel Aiba

Martin Huelsmeyer

The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.

Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3)

Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof

Growing community of inventors

Freising, Germany

Michaela Aloe